Anesthetic GEL for painless non-invasive dental procedures

Abstract

Disclosed herein is an advanced anesthetic gel formulation designed for painless, non-invasive dental procedures. The gel incorporates lidocaine hydrochloride and prilocaine hydrochloride as the primary anesthetics, supported by carbomer 940 for viscosity control. Sodium chloride is added to improve electrical conductivity, while triethanolamine maintains an optimal pH balance. Glycerin functions as a humectant to reduce tissue irritation, and allantoin offers anti-inflammatory properties. Phenoxyethanol is included to prevent microbial growth, ensuring the gel's safety and stability. The preparation method involves dissolving these components in purified water, creating a gel that enables effective, non-invasive dental anesthesia through iontophoresis, significantly enhancing patient comfort and procedural efficiency.

Description

ANESTHETIC GEL FOR PAINLESS NON-INVASIVE DENTAL PROCEDURESTECHNICAL FIELD

[0001] The present disclosure pertains to the fields of dentistry and biomedical engineering. Specifically, it relates to a biocompatible topical anesthetic gel designed to deliver localized, non-invasive anesthesia in dental procedures through iontophoresis. This invention offers an effective alternative to traditional needle -based infiltration anesthesia by enhancing depth of penetration and patient comfort.BACKGROUND ART

[0002] In the realm of dentistry, the administration of local anesthesia is a crucial step in ensuring patient comfort during various dental procedures. Traditionally, this has been achieved through needle -based infiltration anesthesia, where anesthetic agents are injected directly into the targeted area. While effective in numbing the region, this method is often accompanied by significant drawbacks, including pain and anxiety associated with needle injections, risk of infections, potential tissue trauma, and post-injection complications. These factors contribute to a less-than-ideal patient experience, especially among individuals with dental phobias or those requiring frequent dental work.

[0003] Topical anesthetic gels have been introduced as an alternative to needle injections, aiming to reduce the initial discomfort of the procedure. These gels are applied to the mucosal surfaces to numb the superficial layers of tissues. However, their effectiveness is limited by the depth of penetration, which is often insufficient for more invasive dental procedures. Consequently, despite their benefits, topical anesthetics have not fully replaced the need for injections in many clinical scenarios, particularly those requiring deeper anesthesia.

[0004] Iontophoresis, a technique that employs a mild electrical current to enhance the transdermal or transmucosal delivery of drugs, has shown promise in addressing the limitations of conventional topical anesthetics. By creating an electrochemical gradient, iontophoresis facilitates the deeper penetration of active pharmaceutical agents into tissues, thereby increasing their therapeutic efficacy. Despite its potential, the application of iontophoresis in dental anesthesia has been limited due to the lack of specialized devices tailored for oral use and compatible anesthetic formulations.

[0005] The present invention seeks to bridge this gap by introducing a biocompatible topical anesthetic gel specifically formulated for use with an iontophoresis device in dental applications. The gel is designed to enhance the delivery of local anesthetics to deeper tissues, providing rapid and effective pain relief without the need for needle injections. By integrating conductive excipients and soothing additives, the gel not only improves the efficiency of iontophoresis but also minimizes irritation and discomfort for the patient.

[0006] One of the primary challenges in developing a suitable anesthetic gel for dental iontophoresis is ensuring biocompatibility and safety. The oral cavity is a sensitive and dynamic environment, necessitating a formulation that is gentle on tissues while maintaining effective anesthetic properties. The invention addresses this by incorporating local anesthetics such as lidocaine and prilocaine at optimal concentrations, along with conductive agents like sodium chloride to enhance the iontophoresis process. Additional ingredients such as glycerin and allantoin are included to provide soothing and anti-inflammatory benefits, ensuring that the gel is well-tolerated by patients.

[0007] Another critical aspect of the invention is the formulation's pH, which is carefully adjusted to a physiologically compatible range of 6.8 to 7.0. This ensures that the gel does not cause irritation or discomfort when applied to the mucosal surfaces. The use of carbomer as a gelling agent helps achieve the desired viscosity, allowing for stable contact with tissues and efficient drug delivery through the iontophoresis device.

[0008] The integration of this advanced anesthetic gel with a specially designed iontophoresis device offers several advantages over traditional methods. The non-invasive nature of the technique eliminates the pain and anxiety associated with needle injections, making it particularly suitable for pediatric, geriatric, and anxious patients. Additionally, the rapid onset of anesthesia and greater depth of penetration achieved through iontophoresis ensure that dental procedures can be performed more efficiently and with enhanced patient comfort.

[0009] In summary, the invention provides a comprehensive solution for non-invasive dental anesthesia, combining a biocompatible topical anesthetic gel with iontophoresis to deliver rapid, effective, and painless anesthesia. This innovative approach addresses the limitations of existing topical anesthetics and offers a safer, more comfortable alternative to needle -based infiltration anesthesia in dentistry. By improving patient experience and clinical outcomes, this invention has the potential to transform dental practice and set a new standard for pain management in dentistry.SUMMARY OF THE DISCLOSURE

[0010] This summary is intended to provide an overview of the subject matter of the present disclosure, and is not intended to identify essential elements or key elements of the subject matter, nor is it intended to be used to determine the scope of the claimed implementations. The proper scope of the present disclosure may be ascertained from the claims set forth below in view of the detailed description below and the drawings.

[0011] The present disclosure introduces a groundbreaking method and system for achieving painless, non-invasive dental anesthesia, revolutionizing traditional needle -based approaches. At the core of this innovation is a meticulously formulated anesthetic gel, combined with a handheld iontophoresis device, designed to deliver rapid, deep, and localized anesthesia without the need for injections. This system addresses the longstanding challenges of patient discomfort, needle phobia, and tissue trauma associated with conventional dental anesthesia methods.

[0012] The anesthetic gel is a sophisticated blend of active and inactive ingredients, optimized for both efficacy and safety. It includes lidocaine hydrochloride (4-5% w / w) and prilocaine hydrochloride (2-3% w / w) as the primary and secondary anesthetics, respectively, ensuring a potent and synergistic numbing effect. The gel’s formulation is further enhanced by carbomer 940 (1-1.5% w / w), which controls viscosity and gelling, and sodium chloride (0.5-1% w / w), which improves electrical conductivity for iontophoresis. Additional components, such as triethanolamine (0.5-1% w / w) for pH adjustment, glycerin (2-3% w / w) for tissue hydration, allantoin (0.5-1% w / w) for anti-inflammatory and soothing properties, and phenoxyethanol (0.1-2% w / w) as a preservative, collectively ensure a stable, biocompatible, and patientfriendly formulation.

[0013] The handheld iontophoresis device is engineered for precision, safety, and ease of use. Its brush-like applicator tip, resembling a compact toothbrush head, integrates 2-4 miniature electrodes made from biocompatible materials (e.g., gold or platinum) to ensure uniform current distribution. A central channel within the tip allows for direct gel delivery to the target site, minimizing waste and enhancing contact with the tissue. The device features adjustable low-level electrical current settings (2-4 mA) to accommodate varying patient sensitivities and procedure types, along with built-in safety mechanisms such as automatic timers, visual / audible alerts, and circuit protection to prevent overexposure or electrical anomalies.The ergonomic, pen-like design, powered by rechargeable or disposable batteries, ensures comfortable handling and operational efficiency.

[0014] This invention represents a paradigm shift in dental anesthesia, offering a needle-free alternative that is particularly beneficial for pediatric, geriatric, and anxious patients. The combination of the bioactive anesthetic gel and the iontophoresis device ensures rapid onset of anesthesia, reduced chair time, and enhanced patient compliance. Clinically, the system is adaptable to a wide range of dental procedures, from routine cleanings to minor surgeries, making it a versatile and cost-effective solution for modern dental practices. By eliminating the discomfort and anxiety associated with needles, this innovation sets a new standard in dental care, paving the way for a future where painless, non-invasive procedures are the norm.BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The drawing figures depict one or more implementations in accord with the present teachings, by way of example only, not by way of limitation. In the figures, like reference numerals refer to the same or similar elements.

[0016] FIG. 1 illustrates a method for preparing an anesthetic gel for painless non-invasive dental procedures, consistent with one or more exemplary embodiments of the present disclosure.DESCRIPTION OF EMBODIMENTS

[0017] In the following detailed description, numerous specific details are set forth by way of examples in order to provide a thorough understanding of the relevant teachings. However, it should be apparent that the present teachings may be practiced without such details. In other instances, well known methods, procedures, components, and / or circuitry have been described at a relatively high-level, without detail, in order to avoid unnecessarily obscuring aspects of the present teachings.

[0018] The following detailed description is presented to enable a person skilled in the art to make and use the methods and devices disclosed in exemplary embodiments of the present disclosure. For purposes of explanation, specific nomenclature is set forth to provide a thorough understanding of the present disclosure. However, it will be apparent to one skilled in the art that these specific details are not required to practice the disclosed exemplary embodiments. Descriptions of specific exemplary embodiments are provided only as representative examples. Various modifications to the exemplary implementations will be readily apparent to one skilled in the art, and the general principles defined herein may be applied to other implementations and applications without departing from the scope of the present disclosure. The present disclosure is not intended to be limited to the implementations shown, but is to be accorded the widest possible scope consistent with the principles and features disclosed herein.

[0019] Disclosed herein is a method for preparing an anesthetic gel for painless non-invasive dental procedures. FIG. 1 shows a method for preparing an anesthetic gel for painless non-invasive dental procedures, consistent with one or more exemplary embodiments of the present disclosure. As shown in FIG. 1, in an exemplary embodiment, method 100 may include a first step 101 of preparing a base solution by dissolving an amount of carbomer 940 in an amount of purified water, a second step 102 of adding an amount of triethanolamine to the base solution, a third step 103 of preparing a secondary solution by dissolving an amount of lidocaine hydrochloride and an amount of prilocaine hydrochloride in an ethanol / water solution, a fourth step 104 of adding the secondary solution to the base solution, a fifth step 105 of adding an amount of sodium chloride to the base solution, a sixth step 106 of adding an amount of glycerin to the base solution, a seventh step 107 of adding an amount of allantoin to the base solution, an eighth step 108 of adding an amount of phenoxyethanol to the base solution, and a ninth step 109 of stirring the base solution for 30 minutes.

[0020] In an exemplary embodiment, in order to implement first step 101 of method 100, an amount of carbomer 940 may be dissolved in an amount of purified water in order to prepare a base solution. In an exemplary embodiment, a weight of the amount of carbomer 940 may be in a range between 1% and 1.5% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, the weight of the amount of carbomer 940 may be 1.25% of the weight of the anesthetic gel. In an exemplary embodiment, in order to implement second step 102 of method 100, an amount of triethanolamine may be added to the base solution. In an exemplary embodiment, a weight of the amount of triethanolamine may be in a range between 0.5% and 1% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, the weight of the amount of triethanolamine may be 0.75% of the weight of the anesthetic gel. In an exemplary embodiment, the amount of triethanolamine may be added to the base solution in order to adjust a PH of the base solution in a range between 6.8 and 7.

[0021] In an exemplary embodiment, in order to implement third step 103 of method 100, an amount of lidocaine hydrochloride and an amount of prilocaine hydrochloride may be dissolved in an ethanol / water solution in order to prepare a secondary solution. In an exemplary embodiment, a weight of the amount of lidocaine hydrochloride may be in a range between 4% and 5% of a weight of the anesthetic gel and a weight of the amount of prilocaine hydrochloride may be in a range between 2% and 3% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, a weight of the amount of lidocaine hydrochloride may be 4.5% of the weight of the anesthetic gel and a weight of the amount of prilocaine hydrochloride may be 2.5% of the weight of the anesthetic gel. In an exemplary embodiment, in order to implement fourth step 104 of method 100, the secondary solution may be added to the base solution.

[0022] In an exemplary embodiment, in order to implement fifth step 105 of method 100, an amount of sodium chloride may be added to the base solution. In an exemplary embodiment, a weight of the amount of sodium chloride may be in a range between 0.5% and 1% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, a weight of the amount of sodium chloride may be 0.75% of the weight of the anesthetic gel. In an exemplary embodiment, in order to implement sixth step 106 of method 100, an amount of glycerin may be added to the base solution. In an exemplary embodiment, a weight of the amount of glycerin may be in a range between 2% and 3% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, a weight of the amount of glycerin may be 2.5% of the weight of the anesthetic gel.

[0023] In an exemplary embodiment, in order to implement seventh step 107 of method 100, an amount of allantoin may be added to the base solution. In an exemplary embodiment, a weight of the amount of allantoin may be in a range between 0.5% and 1% of the weight of the anesthetic gel. In an exemplary embodiment, a weight of the amount of allantoin may be 0.75% of the weight of the anesthetic gel. In an exemplary embodiment, in order to implement eighth step 108 of method 100, an amount of phenoxyethanol may be added to the base solution. In an exemplary embodiment, a weight of the amount of phenoxyethanol may be in a range between 0.1% and 2% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, a weight of the amount of phenoxyethanol may be 1.1% of the weight of the anesthetic gel. In an exemplary embodiment, in order to implement ninth step 109 of method 100, the base solution may be stirred for a period of time so that a uniform and transparent gel is obtained. In an exemplary embodiment, the base solution may be stirred for 30 minutes.

[0024] Disclosed herein is also an anesthetic gel for painless non-invasive dental procedures. In an exemplary embodiment, the anesthetic gel may include an amount of purified water, an amount of lidocaine hydrochloride, an amount of prilocaine hydrochloride, an amount of carbomer 940, an amount of sodium chloride, an amount of triethanolamine, an amount of glycerin, an amount of allantoin, and an amount of phenoxyethanol. It should be noted that purified water functions as the base solvent, providing a stable medium for the formulation. Lidocaine hydrochloride serves as the primary local anesthetic, ensuring effective numbing of the targeted area. Prilocaine hydrochloride complements lidocaine as a secondary anesthetic, working synergistically to enhance the overall anesthetic effect. Carbomer 940 is included to control gelling and viscosity, ensuring the gel maintains optimal consistency for application.

[0025] Sodium chloride is added to improve electrical conductivity, facilitating the iontophoresis process. Triethanolamine is utilized to adjust the pH of the formulation, ensuring it remains within a physiologically compatible range. Glycerin acts as a humectant, reducing tissue irritation and maintaining moisture levels. Allantoin provides anti-inflammatory and soothing properties, aiding in patient comfort. Lastly, phenoxyethanol is incorporated to prevent microbial growth, ensuring the formulation remains safe and stable for use.

[0026] In an exemplary embodiment, a weight of the amount of lidocaine hydrochloride may be in a range between 4% and 5% of a weight of the anesthetic gel. Specifically, in an exemplary embodiment, the weight of the amount of lidocaine hydrochloride may be 4.5% of the weight of the anesthetic gel. In an exemplary embodiment, a weight of the amount ofprilocaine hydrochloride may be in a range between 2% and 3% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, the weight of the amount of prilocaine hydrochloride may be 2.5% of the weight of the anesthetic gel. In an exemplary embodiment, a weight of the amount of carbomer 940 may be in a range between 1% and 1.5% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, the weight of the amount of carbomer 940 may be 1.25% of the weight of the anesthetic gel.

[0027] In an exemplary embodiment, a weight of the amount of sodium chloride may be in a range between 0.5% and 1% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, the weight of the amount of sodium chloride may be 0.75% of the weight of the anesthetic gel. In an exemplary embodiment, a weight of the amount of triethanolamine may be in a range between 0.5% and 1% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, the weight of the amount of triethanolamine may be 0.75% of the weight of the anesthetic gel.

[0028] In an exemplary embodiment, a weight of the amount of glycerin may be in a range between 2% and 3% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, the weight of the amount of glycerin may be 2.5% of the weight of the anesthetic gel. In an exemplary embodiment, a weight of the amount of allantoin may be in a range between 0.5% and 1% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, a weight of the amount of allantoin may be 0.75% of the weight of the anesthetic gel. In an exemplary embodiment, a weight of the amount of phenoxyethanol may be in a range between 0.1% and 2% of the weight of the anesthetic gel. Specifically, in an exemplary embodiment, a weight of the amount of phenoxyethanol may be 1.1% of the weight of the anesthetic gel.

[0029] Disclosed herein is also a handheld iontophoresis device for non-invasive dental anesthesia. In an exemplary embodiment, the handheld iontophoresis device may include a brush-like applicator tip (similar to a toothbrush head) containing electrodes for uniform current distribution, an adjustable, low-level electrical current (approximately 2-4 mA) to facilitate penetration of anesthetic agents into gingival tissues, and built-in safety systems, including an automatic timer and visual / audible alerts.

[0030] In an exemplary embodiment, the brush-like applicator tip (electrode assembly) may have some features. In an exemplary embodiment, the tip may be brush-like, resembling a compact toothbrush head. In an exemplary embodiment, a length of the brush-like applicatortip may be between 10 mm and 15 mm. In an exemplary embodiment, a width of the brushlike applicator tip may be between 5 mm and 8 mm. in an exemplary embodiment, the design of the brush-like applicator tip may allow for easy placement on the gingiva or other intraoral sites. In an exemplary embodiment, electrode configuration of the brush-like applicator tip may have some features. In an exemplary embodiment, 2-4 miniature electrodes may be integrated into or around the brush head, ensuring even current distribution across the target area. In an exemplary embodiment, electrodes may be made from biocompatible metals (e.g., gold or platinum) or conductive materials coated with silicone or medical-grade polymers.

[0031] In an exemplary embodiment, the brush-like applicator tip may include a central channel for gel delivery. In an exemplary embodiment, it may be a central lumen through which the anesthetic gel may be dispensed directly onto the soft tissue. In an exemplary embodiment, this may reduce wastage and allows direct contact of the gel with the site of application before current is applied. In an exemplary embodiment, the brush-like applicator tip may be a detachable tip enabling autoclaving, cold sterilization, or single-use disposable tips to maintain high standards of hygiene. In an exemplary embodiment, there may be medical-grade silicone or similar material around the electrodes to protect device internals from saliva and fluids.

[0032] In an exemplary embodiment, the handheld iontophoresis device may include a penlike or slim handle approximately 12-15 cm in length, weighing less than 150 g for easy handling and ergonomic comfort. In an exemplary embodiment, the handheld iontophoresis device may include a power supply powered by rechargeable Li-ion batteries or disposable AA / AAA batteries. It may also include built-in voltage regulation to ensure a stable low-level current output (2-4 mA). it may also include adjustable current settings (2 mA, 3 mA, 4 mA) to accommodate different patient sensitivities and procedure types. It may also include LED or LCD display showing the current intensity and remaining time. It may also include Automatic Timer (5-10 minutes). In an exemplary embodiment, the device stops current flow after a preset time to prevent overexposure. It may also include safety alerts which may be associated with audible or vibrational cues indicating process completion or battery depletion.

[0033] In an exemplary embodiment, the handheld iontophoresis device may be with additional safety measures. In an exemplary embodiment, it may include constant current driver which maintains a steady current level, regardless of minor changes in tissue conductivity. It may also include circuit protection. In an exemplary embodiment, the system powers off or reduces current if an unexpected spike or short circuit occurs.

[0034] As discussed above, the disclosed invention in this disclosure offers a paradigm shift in dental anesthesia by eliminating the discomfort and anxiety associated with needle -based infiltration methods. The innovative iontophoresis-based device, coupled with a biocompatible anesthetic gel, provides rapid and deep localized anesthesia, transforming the dental experience into a more pleasant and less stressful one. Patients, particularly those with needle phobia, pediatric, geriatric, or anxious individuals, stand to gain immensely from this non-invasive approach that ensures a virtually painless procedure with minimal risk of infection or tissue trauma.

[0035] The device's ergonomic design and user-friendly features, such as a brush-like applicator tip and adjustable low-level electrical current, facilitate precise and uniform delivery of the anesthetic. This ensures that the anesthetic agents penetrate deeply into the gingival tissues, achieving a more effective and faster onset of anesthesia. The integrated safety systems, including automatic timers and visual / audible alerts, add an extra layer of protection, ensuring that the application is safe and controlled, reducing the likelihood of complications.

[0036] Moreover, the advanced formulation of the bioactive anesthetic gel enhances the iontophoresis efficiency, thanks to its conductive excipients and soothing additives. The combination of lidocaine and prilocaine offers a potent and broad anesthetic effect, while the gel’s pH compatibility and anti-inflammatory components minimize any potential irritation. The result is a more comfortable experience for the patient, with the added benefit of reduced chair time and a greater likelihood of treatment acceptance.

[0037] Clinically, the invention's adaptability to various procedures, from scaling and root planing to minor oral surgeries and restorative treatments, positions it as a versatile tool in the dental arsenal. Its cost-effectiveness, through reduced reliance on disposable needles and anesthetic cartridges, combined with the potential for sterilizable or single-use device tips, underscores its practicality for modern dental practices. This invention not only elevates patient comfort and compliance but also sets a new standard in the field of dental anesthesia, heralding a future where needle-free dental procedures are the norm.Example 1

[0038] In the first example, the invention is demonstrated in the context of dental scaling, a procedure requiring precise and effective anesthesia of the gingival tissues. The device is set to deliver a 2 mA current for a duration of five minutes, during which a gel formulationcontaining 4% lidocaine and 2% prilocaine, balanced at a pH of 7.0, is applied to the gingival margin. The unique combination of iontophoresis and a biocompatible anesthetic gel facilitates the deep penetration of anesthetic agents, approximately 3-4 mm into the tissue. This method ensures that the targeted area is adequately numbed, providing significant relief without the necessity of a traditional needle injection. The streamlined, non-invasive process underscores the device's potential to enhance patient comfort and compliance, especially for those apprehensive about needle -based procedures.Example 2

[0039] The second example illustrates the application of the device in a minor soft tissue biopsy, a procedure often associated with patient discomfort due to its invasive nature. Here, the device is configured to administer a 3-mA current over an eight-minute period, using a more potent gel formulation containing 5% lidocaine, 3% prilocaine, and 1% sodium chloride to enhance electrical conductivity. After a preparatory rinse, the device's applicator tip is positioned at the biopsy site, and the iontophoresis process begins. The electrical current aids in the efficient transport of anesthetic agents, achieving a deeper and more effective anesthesia. As a result, the biopsy can be conducted with minimal discomfort to the patient, eschewing the need for conventional needle injections and thereby reducing procedural anxiety and associated risks.

[0040] The above examples elucidate the invention's adaptability and efficacy in various dental procedures, showcasing its ability to deliver rapid and profound anesthesia. The device's sophisticated mechanism of iontophoresis, paired with the meticulously formulated anesthetic gel, ensures that patients receive optimal care with minimal discomfort. This integrated approach not only transforms the procedural experience but also paves the way for advancements in dental practice by promoting needle-free and patient-friendly anesthesia solutions.

[0041] While the foregoing has described what may be considered to be the best mode and / or other examples, it is understood that various modifications may be made therein and that the subject matter disclosed herein may be implemented in various forms and examples, and that the teachings may be applied in numerous applications, only some of which have been described herein. It is intended by the following claims to claim any and all applications, modifications and variations that fall within the true scope of the present teachings.

[0042] Unless otherwise stated, all measurements, values, ratings, positions, magnitudes, sizes, and other specifications that are set forth in this specification, including in the claims that follow, are approximate, not exact. They are intended to have a reasonable range that is consistent with the functions to which they relate and with what is customary in the art to which they pertain.

[0043] The scope of protection is limited solely by the claims that now follow. That scope is intended and should be interpreted to be as broad as is consistent with the ordinary meaning of the language that is used in the claims when interpreted in light of this specification and the prosecution history that follows and to encompass all structural and functional equivalents.

[0044] Except as stated immediately above, nothing that has been stated or illustrated is intended or should be interpreted to cause a dedication of any component, step, feature, object, benefit, advantage, or equivalent to the public, regardless of whether it is or is not recited in the claims.

[0045] It will be understood that the terms and expressions used herein have the ordinary meaning as is accorded to such terms and expressions with respect to their corresponding respective spaces of inquiry and study except where specific meanings have otherwise been set forth herein. Relational terms such as first and second and the like may be used solely to distinguish one entity or action from another without necessarily requiring or implying any actual such relationship or order between such entities or actions. The terms “comprises,” “comprising,” or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. An element proceeded by “a” or “an” does not, without further constraints, preclude the existence of additional identical elements in the process, method, article, or apparatus that comprises the element.

[0046] The Abstract of the Disclosure is provided to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. In addition, in the foregoing Detailed Description, it can be seen that various features are grouped together in various implementations. This is for purposes of streamlining the disclosure, and is not to be interpreted as reflecting an intention that the claimed implementations require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matterlies in less than all features of a single disclosed implementation. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separately claimed subject matter.

[0047] While various implementations have been described, the description is intended to be exemplary, rather than limiting and it will be apparent to those of ordinary skill in the art that many more implementations and implementations are possible that are within the scope of the implementations. Although many possible combinations of features are shown in the accompanying figures and discussed in this detailed description, many other combinations of the disclosed features are possible. Any feature of any implementation may be used in combination with or substituted for any other feature or element in any other implementation unless specifically restricted. Therefore, it will be understood that any of the features shown and / or discussed in the present disclosure may be implemented together in any suitable combination. Accordingly, the implementations are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.

Claims

What is claimed is:

1. An anesthetic gel for painless non-invasive dental procedures, the anesthetic gel comprising:an amount of purified water;an amount of lidocaine hydrochloride, a weight of the amount of lidocaine hydrochloride being 4.5% of the weight of the anesthetic gel;an amount of prilocaine hydrochloride, a weight of the amount of prilocaine hydrochloride being 2.5% of the weight of the anesthetic gel;an amount of carbomer 940, a weight of the amount of carbomer 940 being 1.25% of the weight of the anesthetic gel;an amount of sodium chloride, a weight of the amount of sodium chloride being 0.75% of the weight of the anesthetic gel;an amount of triethanolamine, a weight of the amount of triethanolamine being 0.75% of the weight of the anesthetic gel;an amount of glycerin, a weight of the amount of glycerin being 2.5% of the weight of the anesthetic gel;an amount of allantoin, a weight of the amount of allantoin being 0.75% of the weight of the anesthetic gel; andan amount of phenoxyethanol, a weight of the amount of phenoxyethanol being 1.1% of the weight of the anesthetic gel.

2. An anesthetic gel for painless non-invasive dental procedures, the anesthetic gel comprising:an amount of purified water;an amount of lidocaine hydrochloride, a weight of the amount of lidocaine hydrochloride being in a range between 4% and 5% of a weight of the anesthetic gel;an amount of prilocaine hydrochloride, a weight of the amount of prilocaine hydrochloride being in a range between 2% and 3% of the weight of the anesthetic gel;an amount of carbomer 940, a weight of the amount of carbomer 940 being in a range between 1% and 1.5% of the weight of the anesthetic gel;an amount of sodium chloride, a weight of the amount of sodium chloride being in a range between 0.5% and 1% of the weight of the anesthetic gel;an amount of triethanolamine, a weight of the amount of triethanolamine being in a range between 0.5% and 1% of the weight of the anesthetic gel;an amount of glycerin, a weight of the amount of glycerin being in a range between 2% and 3% of the weight of the anesthetic gel;an amount of allantoin, a weight of the amount of allantoin being in a range between 0.5% and 1% of the weight of the anesthetic gel; andan amount of phenoxyethanol, a weight of the amount of phenoxyethanol being in a range between 0.1% and 2% of the weight of the anesthetic gel;3. A method for preparing an anesthetic gel for painless non-invasive dental procedures, the anesthetic gel comprising:preparing a base solution by dissolving an amount of carbomer 940 in an amount of purified water, a weight of the amount of carbomer 940 being 1.25% of the weight of the anesthetic gel;adding an amount of triethanolamine to the base solution, a weight of the amount of triethanolamine being 0.75% of the weight of the anesthetic gel;preparing a secondary solution by dissolving an amount of lidocaine hydrochloride and an amount of prilocaine hydrochloride in an ethanol / water solution, a weight of the amount of lidocaine hydrochloride being 4.5% of the weight of the anesthetic gel, a weight of the amount of prilocaine hydrochloride being 2.5% of the weight of the anesthetic gel;adding the secondary solution to the base solution;adding an amount of sodium chloride to the base solution, a weight of the amount of sodium chloride being 0.75% of the weight of the anesthetic gel;adding an amount of glycerin to the base solution, a weight of the amount of glycerin being 2.5% of the weight of the anesthetic gel;adding an amount of allantoin to the base solution, a weight of the amount of allantoin being 0.75% of the weight of the anesthetic gel;adding an amount of phenoxyethanol to the base solution, a weight of the amount of phenoxyethanol being 1.1% of the weight of the anesthetic gel; andstirring the base solution for 30 minutes.

Images